radiolabelled SGM-101 (Surgimab)

N/A

Report date: 2025/06/11 11:18:55

Base Information

Drug Nameradiolabelled SGM-101 (Surgimab)

Drug Alias NameN/A

ClassificationRadiation-emitting productsDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonists

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSurgimab Sas

China Registration ClassN/A

Develop Information

Active CompaniesSurgimab Sas

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A